Has Anjana Myneni, MD received payments from drug or device companies?

Yes. Drug and device makers reported $14,384 in general payments to Anjana Myneni, MD across 692 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anjana Myneni, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anjana Myneni, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anjana Myneni, MD

Endocrinology, Diabetes & Metabolism · Bloomfield Hills, MINPI 1316063274

Payments from drug & device makers

$14,384in general payments, 2019–2025

Across 692 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$2K
Lilly USA, LLC$1K
Medtronic$821
Mannkind Corporation$739
Amgen$662
Bayer$594
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	92	$1,795
Lilly USA, LLC	80	$1,446
Medtronic(2 entities)	37	$821
Mannkind Corporation	44	$739
Amgen(2 entities)	35	$662
Bayer	27	$594
Corcept Therapeutics	32	$593
Dexcom, Inc.	18	$582
Sanofi-aventis U.S. LLC	29	$552
Xeris Pharmaceuticals, Inc.	27	$473
Cequr Corporation	4	$449
AstraZeneca(2 entities)	22	$388
Radius Health, Inc.	18	$379
Boehringer Ingelheim	16	$311
AbbVie	14	$299
Abbott	12	$295
Senseonics, Incorporated	7	$280
Lifescan, Inc.	17	$272
Amneal Pharmaceuticals LLC	11	$219
Ascendis Pharma Endocrinology Inc	5	$200
BD	11	$198
Nevro Corp.	3	$173
Recordati_rare_diseases_inc.	8	$169
Ipsen Biopharmaceuticals, Inc	8	$155
Alvogen Inc	7	$147
Ascensia Diabetes Care US Inc.	8	$146
Clarus Therapeutics Inc.	2	$137
Ultragenyx Pharmaceutical Inc.	6	$122
Insulet Corporation	5	$120
Amarin Pharma, Inc.	7	$119
Madrigal Pharmaceuticals	3	$103
Vivus LLC	5	$95
Amphastar Pharmaceuticals, Inc.	5	$90
Averitas Pharma Inc.	3	$85
Johnson & Johnson	5	$77
Neurocrine Biosciences, Inc.	3	$76
Amryt Pharma Holdings Ltd	5	$73
Embecta Corp.	4	$72
Kyowa Kirin, Inc.	3	$72
Zealand Pharma US, Inc.	3	$63
Valeritas, Inc.	3	$62
Takeda Pharmaceuticals U.S.A., Inc.	2	$62
BETA Bionics, Inc.	4	$60
Shire North American Group Inc	3	$58
Merck	4	$58
Chiesi USA, Inc.	3	$51
Pfizer	2	$51
Tandem Diabetes Care, Inc.	2	$46
Companion Medical, Inc.	2	$43
Esperion Therapeutics, Inc.	2	$32
Tolmar, Inc.	2	$32
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$31
GRT US Holding, Inc.	2	$28
Sequel Med Tech, LLC	1	$23
Verity Pharmaceuticals Inc.	1	$19
EUSA Pharma (US) LLC	1	$18
IBSA Pharma Inc.	1	$17
Antares Pharma, Inc.	1	$14
Aegerion Pharmaceuticals, Inc.	1	$14
Alfasigma USA, Inc.	1	$13

How this compares

$14,384 in reported general payments places this provider in the 75th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$74,721

Medicare patients

162

Services billed

1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Bloomfield Hills

George GrunbergerBloomfield Hills$1.9M
Tobias ElseAnn Arbor$3.5M
Elif OralAnn Arbor$2.9M
Jamal HammoudFlint$2.6M
Lowell SchmeltzFarmington Hills$2.3M
Richard AuchusAnn Arbor$1.3M
Ariel BarkanAnn Arbor$553K
Gary EdelsonFarmington Hills$503K
Michael BrennanSaint Clair Shores$433K
Abdulsalam Al KassabRochester Hills$351K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →